Protection of chickens with or without maternal antibodies against both Marek's and Newcastle diseases by one-time vaccination with recombinant vaccine of Marek's disease virus type 1.
We constructed a stable recombinant Marek's disease virus type 1 (rMDV1) expressing the fusion protein (F) of Newcastle disease virus (NDV) by inserting the coding sequence within the US10 gene of MDV1 by homologous recombination and designated this as rMDV1-US10L(F). The NDV-F protein was significantly expressed under control of the SV40 late promoter in cultured cells infected with the rMDV1. To examine the protective efficacy of the rMDV1, specific pathogen-free (SPF) chickens were vaccinated with rMDV1 at one-day-old. Almost all birds (> 95%) were protected from NDV challenge via intramuscular, ocular, intranasal and intratrachial routes at 4 weeks after vaccination. The rMDV1 showed 100% protection against virulent MDV1 challenge in SPF chickens. Antibody responses against NDV-F and MDV1 antigens were observed at least up to 11 weeks after immunization. When the sera from chickens vaccinated with the rMDV1 were examined for the presence of anti-NDV-F antibody on the day of NDV challenge, the vaccinated bird group which did not survive from NDV challenge were found to show lower antibody titers than the surviving group. The rMDV1 also provided sufficient protection against NDV and MDV1 challenges in commercial chickens with maternal antibodies against NDV-F and MDV1 antigens.
Sakaguchi
M
M
Chemo-Sero Therapeutic Research Institute, Kikuchi Research Center, Kumamoto, Japan.
Nakamura
H
H
Sonoda
K
K
Okamura
H
H
Yokogawa
K
K
Matsuo
K
K
Hira
K
K
D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis*; D002478:Cells, Cultured; D002645:Chickens; D004279:DNA, Viral / Q000032:analysis; D005814:Genes, Viral; D008381:Herpesvirus 2, Gallid / Q000276:immunology*; D007115:Immunization Schedule; D008380:Marek Disease / Q000276:immunology / Q000517:prevention & control*; D009521:Newcastle Disease / Q000517:prevention & control*; D014614:Vaccines, Synthetic; D014765:Viral Vaccines
D000914:Antibodies, Viral; D004279:DNA, Viral; D014614:Vaccines, Synthetic; D014765:Viral Vaccines